A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma

Renuka M; Praveen Panchaksharimath; Archana Shivanna

doi:10.5455/njppp.2023.13.08416202303092023

2024, Vol: 14, Issue: 4

14 / 4Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Online Publishing Date:
12 / 09 / 2023

Natl J Physiol Pharm Pharmacol. 2024; 14(4):

doi: 10.5455/njppp.2023.13.08416202303092023

A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma

Renuka M, Praveen Panchaksharimath, Archana Shivanna.

Abstract
Background: Non-responding to standard doses of inhalational corticosteroids (ICS) remains a challenge in the management of asthma, requiring add-on therapy. Acebrophylline, a theophylline derivative, with multiple mechanisms of action and properties, could work as a suitable alternative to montelukast as an add-on therapy.

Aims and Objectives: The aim of this study was to compare the efficacy and safety of montelukast versus acebrophylline as an add-on therapy to ICS in the treatment of bronchial asthma.

Materials and Methods: One hundred bronchial asthma patients, fulfilling inclusion/exclusion criteria, were enrolled and randomized in a 1:1 ratio into two groups of 50 each to receive either oral montelukast 10 mg OD or oral acebrophylline 200 mg OD with budesonide. Inhaled salbutamol was permitted as rescue medication during acute exacerbations. Primary outcome measures were change in pulmonary function test (PFT) parameters and asthma control questionnaire (ACQ) scores at baseline and 12 weeks. Adverse events, if any were recorded.

Results: There was a statistically significant difference in the improvement of mean PFT parameters at the end of 12 weeks in the montelukast group (P < 0.001), but not in acebrophylline group (P = 0.253). Montelukast was more efficacious than acebrophylline in improving PFT parameters at 6 and 12 weeks. Both treatment modalities significantly improved ACQ score at 12 weeks (P < 0.001), the difference between two groups was not statistically significant (1.4 ± 0.53 in Group A vs. 1.32 ± 0.44 in Group B, P = 0.436). No significant adverse effects were seen in both groups.

Conclusion: Montelukast, with low-dose ICS, had better efficacy over acebrophylline. Both montelukast and acebrophylline improved the quality of life in mild-to-moderate persistent asthma patients by decreasing nocturnal symptoms and the need for rescue medications.

Key words: Montelukast; Acebrophylline; Bronchial Asthma; Corticosteroids

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Renuka M Articles by Praveen Panchaksharimath Articles by Archana Shivanna
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

M R, Panchaksharimath P, Shivanna A. A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma. Natl J Physiol Pharm Pharmacol. Online First: 12 Sep, 2023. doi:10.5455/njppp.2023.13.08416202303092023

Web Style

M R, Panchaksharimath P, Shivanna A. A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma. https://www.njppp.com/?mno=166528 [Access: March 14, 2024]. doi:10.5455/njppp.2023.13.08416202303092023

AMA (American Medical Association) Style

M R, Panchaksharimath P, Shivanna A. A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma. Natl J Physiol Pharm Pharmacol. Online First: 12 Sep, 2023. doi:10.5455/njppp.2023.13.08416202303092023

Vancouver/ICMJE Style

M R, Panchaksharimath P, Shivanna A. A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma. Natl J Physiol Pharm Pharmacol, [cited March 14, 2024]; Online First: 12 Sep, 2023. doi:10.5455/njppp.2023.13.08416202303092023

Harvard Style

M, R., Panchaksharimath, . P. & Shivanna, . A. (2024) A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma. Natl J Physiol Pharm Pharmacol, Online First: 12 Sep, 2023. doi:10.5455/njppp.2023.13.08416202303092023

Turabian Style

M, Renuka, Praveen Panchaksharimath, and Archana Shivanna. 2024. A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 12 Sep, 2023. doi:10.5455/njppp.2023.13.08416202303092023

Chicago Style

M, Renuka, Praveen Panchaksharimath, and Archana Shivanna. "A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma." National Journal of Physiology, Pharmacy and Pharmacology Online First: 12 Sep, 2023. doi:10.5455/njppp.2023.13.08416202303092023

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

M, R., Panchaksharimath, . P. & Shivanna, . A. (2024) A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 12 Sep, 2023. doi:10.5455/njppp.2023.13.08416202303092023

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272